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Multiple myeloma (MM) is a hematological malignancy caused by a microenviromentally
aided persistence of plasma cells in the bone marrow. Monoclonal plasma cells often
secrete high amounts of immunoglobulin free light chains (FLCs) that could induce tissue
damage. Recently, we showed that FLCs are internalized in endothelial and myocardial
cell lines and secreted in extracellular vesicles (EVs). MM serum derived EVs presented
phenotypic differences if compared with monoclonal gammopathy of undetermined sig-
nificance (MGUS) serum derived EVs suggesting their involvement in MM pathogenesis
or progression. To investigate the effect of circulating EVs on endothelial and myocardial
cells, we purified MM and MGUS serum derived EVs with differential ultracentrifugation
protocols and tested their biological activity. We found that MM and MGUS EVs induced
different proliferation and internalization rates in endothelial and myocardial cells, thus we
tried to find specific targets in MM EVs docking and processing. Pre-treatment of EVs
with anti-FLCs antibodies or heparin blocked the MM EVs uptake, highlighting that FLCs
and glycosaminoglycans are involved. Indeed, only MM EVs exposure induced a strong
nuclear factor kappa B nuclear translocation that was completely abolished after anti-FLCs
antibodies and heparin pre-treatment. The protein tyrosine kinase c-src is present on MM
circulating EVs and redistributes to the cell plasma membrane after MM EVs exposure.
The anti-FLCs antibodies and heparin pre-treatments were able to block the intracellular re-
distribution of the c-src kinase and the subsequent c-src kinase containing EVs production.
Our results open new insights in EVs cellular biology and in MM therapeutic and diagnostic
approaches.
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INTRODUCTION
Extracellular vesicles (EVs) are emerging as pleiotropic actors in
intercellular signaling. The discovery of exosome (a specific sub-
population of EVs) mediated transfer of specific mRNAs and
miRNAs (1) opened the door for EVs research in cancer biogenesis
and progression. Indeed, EVs carry a broad number of cargos such
as molecules that take part in determining cell identity, signaling
pathways, and deregulation in many cancer forms.
Exosomes are the most attractive models in EVs interplay
studies because they originate from specific intracellular compart-
ments such as endosomes and multivesicular bodies. Moreover,
growing evidences show that tumors constitutively shed exo-
somes with immunosuppressive effects regulating tumor growth,
invasion, angiogenesis, and metastasis (2).
Evs involvement in multiple myeloma (MM) is starting to
be unveiled too. It has been published that normal and MM
bone marrow–mesenchymal stem cells (BM–MSC)-derived exo-
somes differentially affect MM cell homing and growth in vivo. A
novel mechanism by which BM–MSCs play an oncogenic role in
MM is the epigenetic transfer of exosomal miRNA to the tumor
clone (3).
Label-free relative quantitative proteomic analysis of circu-
lating MM EVs identified an EVs specific protein content (4),
while we showed that monoclonal gammopathy of undetermined
significance (MGUS) derived EVs are different from those pro-
duced in MM (5). Indeed, we observed a significant increase in
EVs production in MM patients, and monoclonal immunoglob-
ulin free light chains (FLCs) were rerouted in the extracellular
space via EVs. The serum vesicles from MM patients contained
the “proto-oncogene” c-src kinase compared to MGUS and con-
trol subjects. It has been shown that constitutive activation of
c-src promotes cell survival, proliferation, and chemoresistance
in MM (6, 7) and our finding highlights the involvement of
EVs as c-src kinase transactivating carriers (5). Specific target-
ing of EVs is probably related to their cellular origin and func-
tion. Cell-specific proteins represent a means by which exosomes
can specifically dock various recipient cells by either interac-
tion with cell-surface adhesion molecules or through interaction
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with cell-surface heparan sulfate proteoglycans (2). Phagocy-
tosis is also involved in specific EVs uptake into the cell in
a cell-type dependent manner (8). As potential targeting sites,
heparan sulfate proteoglycans have been shown to function as
internalizing receptors of cancer cell-derived EVs (9). Further-
more, glycosaminoglycans (GAGs) are involved in FLCs fibril-
lation and amyloidogenesis: the evidences that amyloid-related
light chain proteins and GAGs, particularly heparin, interact, sug-
gest that the therapeutic use of GAGs antagonists to prevent
amyloidosis (10).
Shed syndecan-1 (CD138), a GAG binding protein, is known
to actively promote myeloma tumor growth, angiogenesis, and
metastasis in MM (11) and patients with high-serum levels
of heparanase develop more severe illness. The mechanism of
heparanase aggressive phenotype priming is in part due to syn-
ergy with the heparan sulfate proteoglycan syndecan-1 to create a
niche within the bone marrow microenvironment, further driving
myeloma growth and dissemination (12, 13). The evidences that
syndecan-1 and heparanase are also involved in exosomes gen-
eration/uptake thus indicate a potential mechanism in MM EVs
trafficking (14).
In the present work, we studied the biological activity of “as
pure as possible” serum EVs. As pure as possible, thus, named EVs
instead of exosomes, because purified serum samples may contain
protein aggregates and ectosomes. At the moment, separation of
ectosomes and exosomes with the same size and density is still
difficult. To investigate the EVs effect on endothelial and myocar-
dial cells we used gradient fraction grade purity EVs populations
and found that MM EVs induce a significant higher prolifera-
tion rate than MGUS EVs. We also found that while MM EVs are
internalized, MGUS EVs are not. Internalization was blocked with
anti-FLCs antibodies or heparin pre-treatment. More strikingly,
we found that MM EVs induced a c-src kinase containing EVs
release and nuclear factor kappa B (NfκB) nuclear translocation
in cultured cells and both processes were blocked by anti-FLCs
antibodies and heparin treatment.
In summary, this paper reports a novel potential use of anti-
FLCs antibodies in MM patients together with heparin analogs.
Furthermore, we propose the EVs-NfκB translocation assay for
monitoring MGUS patients.
MATERIALS AND METHODS
ETHICS STATEMENT AND SAMPLE COLLECTION
Serum samples were collected in the Laboratory of Clini-
cal Biochemistry, Azienda Ospedaliera Spedali Civili of Bres-
cia (AOSCB). After routine analysis, waste serum samples were
coded, anonymized and frozen at −80°C: monoclonal compo-
nents were detected by high-resolution agarose gel electrophore-
sis/immunofixation (Interlab). Immunoglobulin FLC concentra-
tion was measured by particle enhanced nephelometry (Freelite
assay, The Binding Site) on a Behring BNII Nephelometer (Dade
Behring). The institutional review board of Azienda Ospedaliera
Spedali Civili of Brescia approved the study in adherence with
the Declaration of Helsinki (REC number: SFLC01). All traceable
identifiers were removed before analysis to protect patient con-
fidentiality and all samples were analyzed anonymously. Samples
analyzed include six patients with diagnosed MM (MM1-6), three
MGUS patients (MGUS1–3), and three healthy donors used as
controls (c1–3).
EVs PURIFICATION AND FRACTIONATION
To obtain heterogenous EVs populations, 1 ml serum sample was
processed with serial centrifugation steps (800× g for 30 min,
16,000× g for 45 min, 100,000× g for 2 h) and the pellets were
re-suspended in 50 µl PBS 1× supplemented with 1:1000 Pro-
tease Inhibitor Cocktail (P.I., Sigma). Reducing sample buffer
was added and the samples were boiled 5 min at 95°C. Sam-
ples were electrophoresed in SDS-PAGE and analyzed by western
blot (WB). The heterogeneous EVs populations were subsequently
processed for further fractionation using a discontinuous sucrose
gradient as described in the next paragraph. Samples were nor-
malized for protein content (Bradford assay) whenever possible;
in alternative, equal volumes of each sample were loaded on an
acrylamide–bisacrylamide gel.
SUCROSE GRADIENT
The heterogeneous EVs populations (200 µg of pelleted proteins)
were re-suspended in 800 µl buffer A (10 mM Tris–HCl 250 mM
sucrose, pH 7.4), loaded at the top of a discontinuous sucrose gra-
dient (15, 20, 25, 30, 40, 60% sucrose in 10 mM Tris–HCl, pH 7.4)
and centrifuged at 100,000× g for 16 h at 4°C (rotor MLS 50, Beck-
man Optima MAX). Twelve fractions with equal volumes (400 µl)
were collected from the top of the gradient, and the vesicles were
pelleted by ultracentrifugation (100,000× g for 2 h). The pellets
were re-suspended in 50 µl of 100 mM Tris, 150 mM NaCl, 1 mM
EDTA supplemented with 1:1000 Protease Inhibitor Cocktail (P.I.,
Sigma). Reducing sample buffer was added and the samples were
boiled 5 min at 95°C. Samples were electrophoresed in SDS-PAGE
and analyzed by WB. Positive fractions containing EV markers
(from 6 to 9, 1.11–1.22 g/cm3) were further investigated by atomic
force microscopy (AFM), scanning electron microscopy (SEM),
and lipid fluorescent labeling.
SCANNING ELECTRON MICROSCOPY (SEM)
Extracellular vesicles were purified from 1 ml serum with serial
centrifugations and fractionated onto a discontinuous sucrose
gradient as described before. Fractions known to be positive for
EV markers were ultra-centrifuged (100,000× g for 2 h), pellets
were re-suspended in 200 µl PBS 1×, and centrifuged (400× g
for 5 min) with a Cytospin4 centrifuge (The Thermo Scientific).
Samples were fixed with 2.5% glutaraldehyde (Sigma) in PBS 1×
for 1 h. After washing twice with PBS 1×, the fixed samples were
dehydrated with an ascending sequence of ethanol (25, 50, 75, 90,
100%). Ethanol was then washed away with high-pressure liquid
carbon dioxide (critical point dryer CO2, Balzers Union). Sam-
ples were analyzed by SEM after gold sputtering (Balzers Union
Sputtering System SCD 040), using a Philips 501 SEM operating
at 15 kV.
ATOMIC FORCE MICROSCOPY (AFM)
Extracellular vesicles were re-suspended in 50 µl of 100 mM Tris,
150 mM NaCl, 1 mM EDTA, and diluted 1:10 with deionized water.
Five to 10 µl of samples were then spotted onto freshly cleaved
mica sheets (Grade V-1, thickness 0.15 mm, size 15 mm× 15 mm).


























































Di Noto et al. Multiple myeloma EVs targeting
All mica substrates were dried at room temperature and analyzed
using a JEOL JSPM-5200, using a Veeco AFM tip or a Mikro-
Masch AFM tip. Images were snapped in tapping mode, scan size
ranged from 0.3 to 15 µm and scan speed ranged from 0.6 to
3.3 ms× clock.
FLUORESCENT LABELING
Extracellular vesicles were re-suspended in Diluent C (PKH67
Green Fluorescent cell linker, Sigma) to a 70 µl final volume.
1.7 µl of PKH67 green fluorescent dye was added to each sam-
ple and incubated at room temperature for 10 min. In alternative,
we labeled EVs with PKH26 red fluorescent dye. The reaction was
stopped adding 70 µl of 1% BSA in PBS 1×. EVs were centrifuged
at 100,000× g for 2 h.
FLOW CYTOMETRY
EVs analysis
Forty microliters of Exo-Flow FACS Magnetic beads [9.1 µm,
400 µl at 10 mg/ml, 1.6× 107 beads/ml (SBI, System Bioscience)]
were coupled with 10 µl of anti-CD63 biotinylated antibody fol-
lowing manufacturer instructions. Afterwards, 100 µg (protein
concentration) of EVs were incubated on a rotating rack at 4°C
overnight for CD63 positive EVs capture. Exosomes-coated beads
were stained on ice for 2 h with PKH26 (Sigma, 1 µl/80 µg of
EVs proteins) and with 10 µl of Exo-FITC exosome stain (SBI,
System Bio-Science) and then analyzed on a FACSCanto II flow
cytometer (BD Biosciences) using the FACSDiva software 2.56 (BD
Biosciences).
Re-suspended cells analysis
Human vein endothelial cells (HVEC) were incubated with
PKH67-labeled EVs for 4 h at 37°C; subsequently, cell mono-
layers were washed with PBS 1×, detached using trypsin, and
re-suspended in PBS 1×. Flow-cytometry analysis was performed
on a FACSCanto II (BD Biosciences) using the FACSDiva soft-
ware 2.56 (BD Biosciences). Gate was set on living cells based
on forward/side scatter properties and a minimum of 103 events
within the gated live population were collected per sample. The
intracellular PKH67-labeled EVs were measured by the peak flu-
orescence intensity shift of PKH67, calculated by the geometric
mean of the population. HVECs were stained with mouse anti
CD31-APC (allophycocyanin) primary antibody. Internalized EVs
were stained with or without PKH67-labeled EVs (unlabeled EVs
were used as cell auto-fluorescence control).
EVs ACETYLCHOLINESTERASE ACTIVITY EVALUATION
Extracellular vesicles acetylcholinesterase activity was assayed fol-
lowing a previously described procedure (15, 16). Briefly, EVs
pellets from 1 ml serum were re-suspended in 100 µl of PBS 1×
and incubated with 1.25 mM acetylthiocholine and 0.1 mM 5,5-
dithiobis (2-nitrobenzoic acid) in a final volume of 400 µl. The
incubation was carried out in cuvettes at 37°C and the absorbance
change was monitored every 5 min at 412 nm (0–30 min). The data
represent the enzymatic activity after 20 min.
PROTEIN/LIPID RATIO CALCULATION
Extracellular vesicles protein concentration from controls (three
patients), MGUS (three patients), and MM (six patients) serum
was quantified with Bradford assay. Samples were normalized for
protein content (200 µg). EVs were PKH67-labeled as described
and re-suspended in 20 µl of loading dye [36% Tris–acetate–EDTA
(TAE), 14% H2O, 50% glycerol]. Ten microliters of fluorescent EVs
were spotted on a nitrocellulose membrane and dots fluorescent
signal were acquired using a G:Box Chemi XT Imaging system
(Syngene). Signals were quantified with the Gene Tools program.
Protein content/lipid fluorescent signal ratio was calculated.
CELL CULTURE
H9C2 (ATCC CRL-1446; tissue: heart/myocardium; cell type:
myoblast) cells were grown in Dulbecco’s modified eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
(Lonza), 1% penicillin/streptomycin (Lonza), 1% glutamine
(Lonza); HVECs (17) were grown in RPMI 1640 supplemented
as DMEM, at 37°C, 5% CO2.
FRACTIONATION OF CYTOPLASMIC, MEMBRANOUS, AND NUCLEAR
COMPONENTS
HVEC monolayer were washed two times with cold PBS 1×,
scraped with PBS-0.1 mM EDTA, and ultra-centrifuged at 800× g
for 10 min at 4°C. The pellet was re-suspended in harvest buffer
(10 mM Hepes pH 7.9, 50 mM NaCl, 0.1 mM EDTA, 0.5% Tri-
ton X-100, and freshly added 1 mM DTT, 10 mM tetrasodium
pyrophosphate, 10 mM NaF), incubated on ice for 5 min, and cen-
trifuged at 800× g for 10 min at 4°C. The supernatant contains
cytosolic and membranous proteins while the pellet, contain-
ing nuclei, was washed with Buffer A (10 mM HEPES pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, and freshly added
1 mM DTT, 1 mM PMSF, 4 µg/ml aprotinin, 2 µg/ml pepstatin)
and centrifuged at 800× g for 10 min at 4°C. After centrifuga-
tion, the pellet was re-suspended in buffer C (10 mM HEPES pH
7.9, 500 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP-40,
and freshly added 1 mM DTT, 1 mM PMSF, 4 µg/ml aprotinin,
2 µg/ml pepstatin) and vortexed 15 min at 4°C. Finally, samples
were centrifuged at 20,000× g for 20 min at 4°C and the super-
natant transferred in a new tube. This final fraction contains the
nuclear extract.
IMMUNOFLUORESCENCE
HVEC were grown on 35 mm glass coverslips until 60–80% con-
fluency and incubated at 37°C with equal amount of serum EVs
[healthy patient (c), MGUS, and MM EVs] or only with starvation
medium for 4 h.
Cellular staining
Cells were washed with PBS 1×, fixed with 3% paraformaldehyde
for 15 min, washed with NH4Cl for 15 min, and permeabilized
with 0.3% saponin in PBS three times for 10 min. Primary anti-
bodies were incubated for 1 h and washed three times for 10 min
with 0.3% saponin in PBS 1×. Secondary antibodies were incu-
bated for 45 min and washed as described above. Coverslips were
mounted using an anti-fade mounting medium (ProLongGold-
Invitrogen) on a glass slide. Fluorescent microscopy was per-
formed on a ZEISS Axiovert 100 microscope using the 63× Zeiss
oil immersion objective. Images were processed with the use of
Image pro-plus 4.5.1.
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Nuclear staining
Cells were washed with PBS 1×, fixed with 4% paraformalde-
hyde for 10 min, permeabilized with 0.2% Triton X-100, 2 mg/ml
BSA, 1 mM NaN3 in PBS on ice three times for 10 min. Then
cells were incubated with blocking solution (0.02% Triton X-100,
3% BSA, 1 mM NaN3 in PBS). Primary antibodies were incu-
bated for 30 min in blocking solution and washed three times for
10 min with wash buffer (PBS, 0.02% Triton X-100, 1.5% BSA,
1 mM NaN3). Secondary antibodies were incubated for 45 min
and washed as described above.
EVs UPTAKE
To evaluate cells internalization rate of MGUS and MM EVs,
HVEC, and H9C2 (40,000 cell/dish of 35 mm) cells were incu-
bated 4 h with PKH67 (Green Fluorescent Cell Linker Kit-Sigma)
labeled EVs (200 µg of proteins) at 37°C. As negative controls
cells were incubated with PKH67 centrifuged 2 h at 100,000× g
without EVs to exclude the presence of PKH67 aggregates. Fur-
thermore, to block endocytosis cells were pre-incubated for 30 min
at 4°C or with nocodazole 20 µM (Sigma) at 37°C. After these
pre-incubations, PKH67-labeled EVs (200 µg) were added and
incubated 4 h, respectively, at 4°C or in the presence of the
drug (18). Intracellular uptake was tested by immunofluores-
cence.
To investigate the EVs uptake mediators, before cell treat-
ment, EVs were incubated with 10 µg of Abs (sheep anti-FLCs or
mouse anti-CD63) for 2 h at 4°C and afterwards EVs were ultra-
centrifuged to separate unbound Abs. In alternative, serum EVs
were pre-treated or not with heparin (Sigma) at a final concen-
tration of 100 ng/ml for 30 min at 4°C. Intracellular uptake was
tested by immunofluorescence and/or flow-cytometry.
PROLIFERATION ASSAY
Eight thousand cells/well (12 multi-well plate) were cultured in
RPMI serum-free and control (n= 3), MGUS (n= 3), MM (n= 6)
derived EVs (50 µg proteins) were added for 24, 48, and 72 h,
respectively. Cell proliferation rates were assessed using crystal vio-
let absorbance. The absorbance values were measured at 540 nm.
We calculated the growth factor index with the “doubling time
online calculator.” The cell doubling time index determines the
dynamics of the cell culture development as average time taken
for a cell to complete the cell cycle within several days (24, 48,
72 h). Average of three independent experiments is shown. T -test
p-values were also calculated.
ANTIBODIES AND IMMUNOBLOTTING
The following antibodies were used in our experiments: mouse
anti-Hsp 70 (Enzo Life Science), rabbit anti-NfκB (Santa Cruz),
rabbit anti c-src (Santa Cruz), mouse anti-CD63 (Millipore),
mouse anti-Tsg 101 (Abcam), mouse anti-α-tubulin (Millipore:
Mab1637), mouse anti-Annexin V (Santa Cruz), mouse anti-
Lamin A/C (Novus), sheep anti-λ FLC and sheep anti-k FLC
antibodies (Bethyl Laboratories, USA and the Binding Site, UK),
and goat anti-Histone H3 (Santa Cruz).
Extracellular vesicles from patients’ serum were obtained as
described before. The supernatants were normalized for pro-
tein concentration (Bradford Assay) when possible (in alternative
equal volumes of each sample were loaded on a acrylamide–
bisacrylamide gel), boiled in reducing SDS sample buffer (80 mM
Tris, pH 6.8, 2% SDS, 7.5% glycerol, 0.01% bromophenol blue)
supplemented with 2% 2-mercaptoethanol (Sigma) for 5 min at
95°C and separated by SDS-PAGE on a acrylamide/bisacrylamide
(10 or 12.5%) gel and analyzed by WB.
To visualize the FLC signal, we performed electrophoresis
under native conditions: samples were re-suspended in non-
reducing sample buffer (50 mM Tris, 2% SDS, 10% glycerol, 0.01%
bromophenol blue pH 6.8) and boiled for 5 min at 95°C.
Afterwards, samples were run in a 12.5% acrylamide–
bisacrylamide SDS 0.4% gel, transferred for 1 h onto a PVDF
membrane and blocked overnight with 5% fat-free milk, 0.05%
Tween-20 in PBS. The PVDF membrane was incubated with the
antibodies described above for 2 h in PBS Tween 0.05+ 1% fat-free
milk. The membranes were washed 3× for 10 min with PBS Tween
0.05% and incubated for 1 h with one of the following secondary
antibodies: rabbit anti-mouse and goat anti-rabbit (Zymed), rab-
bit anti goat, and donkey anti-sheep (Jackson Immuno Research).
Table 1 | Description of the patients involved in the study.
Patients Disease k FLC (mg/l) λ FLC (mg/l) Ratio S-IF U-IF IgA mg/dl IgG mg/dl IgM mg/dl Creatinine (mg/dl)
c 1 Healthy 18.4 13.5 1.36 neg. neg. 159 1560 137 0.65
c 2 Healthy 20.1 8.9 2.26 neg. neg. 96 1130 129 0.51
c 3 Healthy 7.4 17.5 0.42 neg. neg. 298 1120 122 0.49
MGUS 1 MGUS 1.69 608 0.00 IgG/λ λ 20.1 2010 28.7 0.6
MGUS 2 MGUS 9.36 284 0.03 IgG/λ neg. 28.7 2220 15.2 0.9
MGUS 3 MGUS 12.9 105 0.12 λ neg. 809 845 66.4 0.64
MM 1 Multiple myeloma 1210 22 55.00 IgG/k k 85.3 729 22.4 0.85
MM 2 Multiple myeloma 1550 4.85 319.59 IgG/k k 26 978 23.4 2
MM 3 Multiple myeloma 1360 6.15 221.14 IgG/k k 46.1 519 17.7 0.8
MM 4 Multiple myeloma 26.6 864 0.03 λ λ 22.6 581 23.7 1.5
MM 5 Multiple myeloma 73.9 1130 0.07 λ λ 174 1150 142 2.6
MM 6 Multiple myeloma 2.45 4450 0.00 λ λ 204 727 22.8 0.9
S-IF, serum immunofixation; U-IF, urine immunofixation; neg., negative.


























































Di Noto et al. Multiple myeloma EVs targeting
FIGURE 1 | Serum EVs characterization. (A) Ultra-centrifuged EVs
were loaded on the top of a 15–60% discontinuous sucrose gradient.
Twelve fractions of equal volume were collected from the top (low
density, fraction 1) to the bottom (high density, fraction 12). Samples
were electrophoresed and analyzed by WB using anti-HSP70, anti-c-src,
anti-CD63, anti-Tsg101, anti-Annexin V, and anti-FLCs antibodies. The
EVs probed markers were identified in fractions 6–9 corresponding to
the buoyant density of 1.11–1.22 g/cm3. (B) EVs were purified with
CD63 Exo-Flow FACS magnetic beads. CD63 coated EVs were then
incubated with PKH26. The data show PKH26 (PE) versus CD63 (FITC)
intensity. The first panel (1) depicts antibody coated beads, the second
(2) MGUS EVs, and the third (3) MM EVs. (C) Scanning electron
microscopy (SEM) imaging of the serum EVs: (i) 80,000×, scale bar
100 nm; (ii) 20,000×, scale bar 1 µm. (D) Atomic force microscopy
(AFM) image of serum EVs: (i) phase, scale bar 110 nm and (ii)
topography, scale bar 1 µm.
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FIGURE 2 | Internalized MM EVs increase HVEC and H9C2 proliferation.
(A) Evaluation of the acetylcholinesterase activity in 50 µg of controls (c, 8
different patients), MGUS (4 patients), and MM (10 patients) crude EVs
samples. Significant differences were determined with Student’s t -test:
*p<0.05, **p<0.01, ***p<0.001. Values were shown as mean SEM of at
least three experiments. (B) Fluorescent (PKH67-labeled) EVs (200 µg of
proteins) from controls, MGUS, and MM patients were re-suspended with
loading buffer [36% TAE (Tris–acetate–EDTA), 14% H2O, 50% glycerol] to a
final volume of 20 µl. Ten microliters were spotted on a nitrocellulose
membrane and dots fluorescent signal were acquired using a G:Box Chemi
XT Imaging system (Syngene). Signals were quantified with the program
Gene Tools. Protein/lipid ratio was quantified for all samples. Mean
values±SEM of at least four different experiments. (C) HVEC and H9C2 cells
in serum-free medium were incubated with 50 µg of controls (c1–3, 3
different patient), MGUS (1–3), and MM (MM 1–6) EVs for 24, 48, and 72 h
and cell proliferation rate (growth factor) was assessed using crystal violet.
Mean values±SEM for three independent experiments are shown.
(Continued )
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FIGURE 2 | Continued
*p<0.05, **p<0.01, ***p<0.001 (D) HVECs were incubated with
PKH67-labeled MGUS and MM EVs (200 µg of proteins) for 4 h at 37°C; as
negative controls cells were pre-incubated for 30 min at 4°C or with
nocodazole 20 µM at 37°C followed by 4 h of exposure to EVs at 4°C or in the
presence of nocodazole. Cells were then washed with PBS 1× and fixed with
3% PFA, permeabilized with 0.3% saponin, and stained with DAPI. Scale bar
5 µm. Coverslips were mounted using an anti-fade mounting medium
(ProLong Gold-Invitrogen) on a glass slide. Fluorescent microscopy was
performed on a ZEISS Axiovert 100 fluorescent microscope using the 63×
Zeiss oil immersion objective. Single sections are shown for each condition.
Images were processed with the use of Image pro-plus 4.5.1. (E) PKH67
fluorescence intensity measurement of internalized MGUS and MM EVs
before and after endocytosis blockage at 4°C, with nocodazole 20 µM.
Internalization rate of PKH67 centrifuged 2 h at 100,000×g without EVs. (100
Cells each experimental point). Images were processed with the use of
Image pro-plus 4.5.1. Mean value and SEM of three independent duplicate
experiments are given.
Blots were detected using Luminata Classic HRP western substrate
(Millipore). Images were acquired using a G:Box Chemi XT Imag-
ing system (Syngene, UK). For densitometric analysis, we took
advantage of the Gene Tools (Syngene, UK) software to compare
the protein quantification of monoclonal bands.
STATISTICAL ANALYSIS
Significant differences among MGUS datasets and other samples
[healthy patient (c) and MM] were determined with Student’s t -
test (Graph Pad). p-Values of <0.05 were considered statistically
significant with *p< 0.05, **p< 0.01, and ***p< 0.001. Values
were shown as mean± SEM (Standard error of the mean) of at
least three experiments.
Significant differences among different treatments on EVs or
cells were determined with Student’s t -test (Graph Pad). *p< 0.05,
**p< 0.01, and ***p< 0.001.
RESULTS
MGUS AND MM SERUM EVs CHARACTERIZATION
We purified serum EVs populations from three control subjects
(c1–3), three MGUS subjects (MGUS 1–3), and six MM patients
(MM 1–6) (Table 1). We decided to use serum instead of plasma
for a first line purification because serum does not contain high
amounts of coagulation factors that could bind and aggregate
EVs. It is well known that EVs from human blood are of high
interest because of diagnostic and therapeutic purposes. Com-
mercially available kits that allow “easy isolation procedures” are
increasingly developed. Such approaches should be taken cau-
tiously because they often fail to distinguish between differently
sized EVs and membrane-free macromolecular aggregates (19).
We used a step gradient protocol without filters and character-
ized the isolated material with AFM, SEM, and flow-cytometry.
As shown in Figure 1A, we obtained four gradient fractions
(from six to nine) containing some typical exosomal markers
and pooled them for subsequent assays and analysis. FACS analy-
sis was performed on PKH26 and CD63 (FITC) labeled EVs
and coated with Exo-Flow FACS magnetic beads. MGUS and
MM patients presented the same profile in the CD63 expres-
sion level (Figure 1B). To better characterize the composition
of serum EVs, we performed morphological analyses using SEM.
Figure 1C shows the presence of vesicles with diameters from 60 to
100 nm in MM serum samples. The pelleted serum derived vesicles
were observed as single vesicles (Figure 1Ci) or vesicles clus-
ters (Figure 1Cii) as previously described for exosomes isolated
from different biological fluids (20). More clearly, the punctate
pattern in AFM, which was performed on native vesicles, indi-
cates that the EVs were pure and free of aggregates contaminants
(Figures 1Di,ii).
SERUM DERIVED MM AND MGUS EVS INDUCE DIFFERENT
ENDOTHELIAL AND MYOCARDIAL PROLIFERATION AND
INTERNALIZATION RATES
In order to verify the amount of EVs in control (c), MGUS, and
MM patients, we evaluated the acetylcholinesterase activity in
EVs purified from 1 ml of serum after serial centrifugation steps
(Figure 2A). MM patients showed the highest enzymatic activity
indicating a higher EVs amount than MGUS and c. We decided to
normalize the EVs protein concentration on lipid content to load
the same EVs amount on cells. EVs from 1 ml serum from control
(three patients), MGUS (three patients), and MM (six patients)
were pelleted after serial centrifugation steps. EVs protein concen-
tration was determined. Samples were normalized for their protein
content (200 µg) of pelletted proteins, EVs lipids were labeled with
PKH67 and spotted on a nitrocellulose membrane (Figure 2B).
Dot fluorescence intensity was acquired using a G:Box Chemi XT
Imaging system (Syngene) and signals were quantified with the
Gene Tools program. Samples protein content was normalized on
the lipid fluorescent signal and ratios were almost identical for
the different EVs preparations (protein/lipid ratio controls 1.02,
MGUS 0.97, MM 1.07, Figure 2B). Consequently, 50 µg of EVs
obtained from control, MGUS, and MM patients were incubated
24, 48, and 72 h respectively, at 37°C, on endothelial and myocar-
dial monolayers. Cell proliferation rates were assessed using crystal
violet absorbance. The growth factor index was calculated with
the “doubling time online calculator” and represented as scale bars
(Figure 2C). Statistical analysis showed a significant difference
between cell monolayers incubated in the presence of different
EVs. Particularly, MM EVs clearly enhanced the proliferation rates.
These data are of interest for further investigation on patients with
amyloidosis because heart failure is the major negative prognostic
factor in such patients (21).
To investigate if the EVs inducible proliferation is uptake depen-
dent, we incubated endothelial monolayers with PKH67 labeled
EVs (200 µg) for 4 h at 37°C. Images of washed and fixed cells
clearly show that only few amounts of MGUS EVs were inter-
nalized in endothelial cells whereas active MM EVs uptake is
evident (Figures 2D,E). This effect is endocytosis-mediated, MM
EVs show an uptake decrease of 69 and 53%, respectively, when
cells are incubated at 4°C or with the endocytosis inhibitor noco-
dazole. We also tested EVs uptake specificity, incubating cells with
PKH67 without EVs and, in this condition, the fluorescent label is
not internalized (Figure 2E). Same experiments were performed
with H9C2 cells and gave similar results (data not shown).
FLCs AND GAGs MEDIATE MM EVs INTRACELLULAR UPTAKE
The long-distance action of EVs is probably related to specific
docking signals in recipient cells. Autocrine models have also
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FIGURE 3 | Free light chains and GAGs mediate MM EVs intracellular
uptake. (A) Fluorescent microscopy analysis of HVECs incubated with MGUS
and MM PKH67-labeled EVs (200 µg of proteins) for 4 h at 37°C. Before cell
treatment, MM EVs were incubated with sheep anti-FLCs (MM+ sh anti FLC),
mouse anti-CD63 (MM+ sh anti-CD63) antibody or with heparin 100 ng/ml
(MM+heparin). (B) Quantitative data from similar experiments analyzed by
flow cytometry. HVECs were labeled with CD31-APC (endothelial marker) and
EVs were labeled with PKH67-FITC. (C) PKH67 fluorescence intensity
measurement of internalized MM EVs incubated with sheep anti-FLCs,
mouse anti-CD63 antibody or with heparin 100 ng/ml (MM+heparin) (100
cells each experimental point) using ImageJ program. Significant differences
were determined with Student’s t -test. Values were shown as mean
values±SEM of at least three experiments. *p<0.05, **p<0.01,
***p<0.001. (D) HVEC and H9C2 cells in serum-free medium were
incubated for 24, 48, and 72 h with 50 µg of MM 5 and MM 6 EVs pre-treated
or not with a polyclonal anti-FLCs antibody. Cell proliferation rate (growth
factor) was assessed using crystal violet. Mean values±SEM for three
independent experiments are shown. *p<0.05, **p<0.01, ***p< 0.001.


























































Di Noto et al. Multiple myeloma EVs targeting
FIGURE 4 | C-src re-distribution in HVECs after EVs exposure.
(Continued)
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FIGURE 4 | Continued
(A) HVECs were incubated with 200 µg of MGUS and MM serum EVs for
4 h at 37°C. Cells were washed with PBS 1× and fixed with 3% PFA,
permeabilized with 0.3% saponin, and stained with the c-src antibody,
followed by Alexa 555-conjugated anti-rabbit immunoglobulin (Ig) and
DAPI. Scale bars, 5 µm. Coverslips were mounted using an anti-fade
mounting medium (ProLong Gold-Invitrogen) on a glass slide. Fluorescent
microscopy was performed on a ZEISS Axiovert 100 fluorescent
microscope using the 63× Zeiss oil immersion objective. Single sections
are shown for each condition. Images were processed with the use of
Image pro-plus 4.5.1. (B) HVECs were treated as described above and
lysates were loaded on the top of a 15–60% discontinuous sucrose
gradient. Twelve fractions of equal volume were collected from the top
(low density, fraction 1) to the bottom (high density, fraction 12). Samples
were electrophoresed and analyzed by WB using anti-c-src and anti-FLCs
antibody. (C) 10×106 HVECs were incubated for 4 h at 37°C with 200 µg
MGUS and MM EVs pre-treated or not with a polyclonal anti-FLCs
antibody (MM+ sheep anti-FLCs), mouse anti-CD63 antibody (MM+m
anti-CD63) or with 10 µg/ml heparin for 2 h at 4°C (MM+heparin). After
incubation, cells were then washed with PBS 1× and treated with trypsin
as described (5) and left in fresh starvation medium for 16 h. Starvation
medium was harvested, centrifuged at 800×g for 30 min, 16,000×g for
45 min, and finally, ultra-centrifuged at 100,000×g for 2 h (see EVs
Purification and Fractionation, Materials and Methods). WB analysis of cell
extracts (homogenate, H, 30 µg) and pellets (p, 25 µl) were performed
with anti-FLCs antibodies and with different vesicles markers (Lamp1,
c-src, annexin V, and FLC). (D) c-src quantification in pellets after different
treatments. Significant differences among the samples were determined
with Student’s t -test: *p<0.05, **p<0.01, ***p<0.001. Values were
shown as mean values±SEM of at least three experiments.
been studied in the modulation of tumor microenvironment. To
test if the different intracellular uptake of MGUS and MM EVs
and the diverse proliferation rates are directly linked, we sought
some targeting molecules to be blocked in EVs docking and sub-
sequent internalization. The presence of FLCs on the external
surface of MM EVs (5) suggested us to test the cellular uptake
after incubation of EVs with polyclonal antibodies against FLCs.
Before cell treatment EVs were incubated with the specific Abs
(anti-FLCs or anti-CD63) for 2 h and afterwards EVs were ultra-
centrifuged to separate unbound Abs. The pelleted EVs were added
in the serum-free cell culture medium and intracellular uptake
tested by immunofluorescence (Figure 3A) and flow-cytometry
(Figure 3B). As shown in Figure 3A, the internalized EVs are
clearly reduced after anti-FLCs treatment. Quantification of pos-
itive stained cells was significantly altered (p< 0.001) in compar-
ison with MM EVs treated cells (Figure 3C). To confirm the
confocal microscopy evidences we trypsinized cell monolayers
after EVs intake and evaluated the PKH67 intensity versus pos-
itive CD31 staining by flow cytometry. Our data show that only
few amounts of FLCs masked EVs are visible in the dot plot analysis
of endothelial cells (Figure 3B). The same results were obtained
with heparin pre-treated EVs but not with an anti-CD63 anti-
bodies (Figures 3A–C). To investigate the active internalization of
EVs and subsequent release of their content as a trigger factor of
increased proliferation rates, we performed the proliferation assay
with or without FLCs masked MM EVs (Figure 3D) on endothe-
lial and myocardial cells and we could observe that masked MM
EVs do not induce the same proliferation rate as MM EVs do.
MM EVs INDUCED c-src RE-DISTRIBUTION AND NfκB NUCLEAR
TRANSLOCATION ARE INTRACELLULAR UPTAKE DEPENDENT
Endocytosis of monoclonal FLCs into the kidney proximal tubu-
lar epithelium promotes a c-src and NfκB dependent generation
of an intrarenal pro-inflammatory, profibrotic process (22). This
pathway promotes the pro-inflammatory production of other
cytokines, such as IL-6 enhancing kidney damage in MM (23–26).
The presence of EVs containing FLCs in urine samples has also
been published (27) suggesting that EVs are probably involved in
different FLCs processing and subsequent inflammation pathways.
To study the potential EVs induced pro-inflammatory response of
endothelial cells, we treated HVECs with MGUS and MM EVs for
4 h at 37°C. Afterwards, we performed an immunofluorescence
assay (see Materials and Methods) to visualize c-src and NfκB
intracellular distribution.
The intracellular c-src distribution was clearly altered after MM
EVs exposure instead of MGUS EVs. Immunofluorescence analy-
sis showed prevalent plasma membrane localization (Figure 4A).
Sucrose gradient fractionation of the cell homogenates indicates
a c-src re-distribution from lower to higher density fractions
(Figure 4B) confirming the immunofluorescence data.
We previously published that (5) MM EVs are able to induce
cellular ex novo secretion of c-src positive EVs, thus, we tested if
anti-FLCs antibodies and heparin were both able to block the c-src
decorated EVs production. We observed a striking reduction of c-
src positive EVs generation and we could not see the same effect
using a different target such as CD63 (Figures 4C,D).
To test the effect of MM EVs on NfκB, we treated HVECs with
MGUS and MM EVs for 4 h at 37°C (Figure 5A). Only HVEC incu-
bated with MM EVs showed a strong NfκB nuclear traslocation.
The effect was completely abolished with MM EVs pre-treated with
anti-FLCs antibodies and heparin. We quantified the nuclear NfκB
fluorescent signal (Figure 5B) and we could observe that cells incu-
bated with MM EVs showed a significant increase in comparison
with other treatments. These data were also strongly confirmed by
WB analysis of nuclear extracts (Figure 5C). To test the efficacy of
the NfκB nuclear traslocation, we also compared our data with a
TNFα pro-inflammatory treatment and with MM EVs pre-coated
with the CD63 antibody: as expected we obtained a significant
NfκB nuclear traslocation compared to control cell (starvation)
both in immunofluorescence and WB analysis (Figures 6A–C).
To confirm that NfκB nuclear traslocation is specifically induced
by MM EVs, we incubated HVECs with MM serum after the ser-
ial ultracentrifugation steps (SN3). Figures 6A–C show that this
treatment do not significantly alter NfκB intracellular distribution
in comparison with control cells.
DISCUSSION
In the present study, we found that the intracellular uptake of
serum MM EVs is enhanced in comparison to MGUS EVs. Our
data show that MM EVs internalization is FLCs and GAGs medi-
ated and we could demonstrate that MM EVs induce the NfκB
nuclear translocation and the c-src kinase containing EVs gen-
eration. Blocking FLCs with anti-FLCs antibodies or masking
the GAGs recognition with heparin altered the EVs intracellular
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FIGURE 5 | Visualization of NfκB nuclear traslocation (A) HVECs were
treated with MGUS or MM serum EVs (200 µg of proteins) for 4 h at
37°C. Before cell treatment, MM EVs were incubated with anti-FLCs
antibody (MM+ sh anti FLC) or with 100 ng/ml of heparin (MM+heparin).
After incubation, cells were washed with PBS 1× and fixed with 4% PFA,
permeabilized with 0.2% Triton X-100, 2 mg/ml BSA, 1 mM NaN3 in PBS,
and stained with anti-NfκB antibody, followed by Alexa 488-conjugated
anti-rabbit immunoglobulin (Ig) and DAPI. Scale bars, 5 µm. Coverslips
were mounted using an anti-fade mounting medium (ProLong
Gold-Invitrogen) on a glass slide. Fluorescent microscopy was performed
on a ZEISS Axiovert 100 fluorescent microscope using the 63× Zeiss oil
immersion objective. Single sections are shown for each condition.
Images were processed with the use of Image pro-plus 4.5.1. (B) Nuclear
NfκB fluorescence intensity was measured after different treatments (100
cells each experimental point) using ImageJ program. Significant
differences were determined with Student’s t -test: *p<0.05, **p< 0.01,
***p<0.001. Values were shown as mean values±SEM of at least three
experiments. (C) WB analysis of cell extracts (homogenate, H, 25 µg) and
nuclear extract (N, 50 µg) were performed with anti-NfκB antibody and
with different nuclear markers (Lamin A/C and Histone H3).
uptake, the NfκB nuclear translocation, and the c-src positive EVs
secretion.
Extracellular vesicles involvement in hematologic malignancies
such as MM is an emerging multifaceted tool for both diagnosis
and therapy (28, 29). The evidences that cancer cells can modulate
metastasis generation by increased and specific EVs secretion led
to the investigation of the interaction between BM–MSC and
MM cells. A mechanism that modulates MM tumor growth was
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FIGURE 6 | Extracellular vesicles induce NfκB nuclear traslocation.
(A) HVECs were treated with serum-free medium for 4 h (starvation),
10 ng/ml TNF-α for 30 min, with MM EVs pre-incubated with anti-CD63
antibody (MM+m anti-CD63) or with MM serum after serial
ultracentrifugation steps (SN3 MM). Cells were fixed with 4% PFA,
permeabilized with 0.2% Triton X-100, 2 mg/ml BSA, 1 mM NaN3 in PBS,
and stained with anti-NfκB antibody, followed by Alexa 488-conjugated
anti-rabbit immunoglobulin (Ig) and DAPI. Scale bars, 5 µm. Coverslips
were mounted using an anti-fade mounting medium (ProLong
Gold-Invitrogen) on a glass slide. Fluorescent microscopy was performed
on a ZEISS Axiovert 100 fluorescent microscope using the 63× Zeiss oil
immersion objective. Single sections are shown for each condition.
Images were processed with the use of Image pro-plus 4.5.1. (B) Nuclear
NfκB fluorescence intensity was measured after different treatments (100
cells each experimental point) using ImageJ program. Significant
differences were determined with Student’s t -test: *p<0.05, **p<0.01,
***p<0.001. Values were shown as mean values±SEM of at least 3
experiments. (C) WB analysis of cell extracts (homogenate, H, 25 µg) and
nuclear extract (N, 50 µg) were performed with anti-NfκB antibody and
with anti-Histone 3 antibody.
identified in the exosomal transfer from BM–MSCs to clonal
plasma cells: MM BM–MSC-derived exosomes promoted MM
tumor growth whereas normal BM–MSC exosomes inhibited the
growth of MM cells (3).
We previously found that circulating EVs are significantly
increased in MM patients in comparison to MGUS subjects
and we identified the c-src kinase as a specific MM EVs
marker (5).
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In the present work, we investigated the effect of circulat-
ing MM EVs on endothelial and myocardial cells: to this aim,
we performed differential ultracentrifugation protocols for serum
EVs purification. To be sure that small protein aggregates were
removed we checked our EVs preparations with morphological
assays, combining SEM and AFM.
Functional activities of EVs can be executed at different lev-
els such as signaling through cell-surface receptors, transfer of
signaling proteins, intracellular release of miRNA, mRNA, and
DNA, or distribution of catalytic activities (30). Upon loading and
release EVs are targeted to recipient cells in a not well understood
fashion. Specific receptors or docking systems may contribute to
the pathophysiology of tumor progression. Thus, we tested first
of all the internalization rate of purified MGUS and MM serum
EVs in endothelial and myocardial cells. We strikingly found that
MM EVs are internalized while MGUS EVs are not, leading to the
hypothesis that MM EVs can behave as signalosomes in the blood
stream.
Heparan sulfate, proteoglycans have been shown to function
as internalizing receptors of cancer cell-derived EVs (9) and are
further involved in immunoglobulin FLCs amyloidogenesis (10).
Because FLCs are actively internalized (31–33), we decided to test
their involvement in EVs uptake together with GAGs and we found
that both are responsible in efficient EVs uptake.
Nuclear factor kappa B transcription factors play a key role
in the survival and proliferation of many kinds of B-cell tumors,
including MM. It was shown that NfκB activation in MM tumors
results mainly from extrinsic signaling that stimulate receptors on
normal plasma cells as well as on pre-malignant MGUS and MM
tumors (34). The NfκB signaling has been rationalized in two inde-
pendent signaling pathways, the canonical and not canonical that
both induce NfκB nuclear translocation and genes transcription.
The Src-family kinases are also involved in such signaling cascades
ultimately leading to cell survival and proliferation (35). Interest-
ingly, NfκB is constitutively active in primary myeloma cells, and
its blockade leads to apoptotic cell death (36).
In our investigation on the pathological effect of MM EVs, we
found that they are capable to induce higher proliferation rates
and to translocate the NfκB into the nucleus. Blocking MM EVs
uptake with polyclonal antibodies directed against FLCs or by EVs
heparin coating clearly abolished the effect. Similar results were
obtained after treating cells with the endocytosis inhibitor noco-
dazole (data not shown). It will be extremely interesting to test
the relevance of EVs induced NfκB nuclear translocation in mon-
itoring MGUS versus MM switching on a larger patient cohort.
Further work is in progress to unravel the major EVs compo-
nent involved in this signaling process. Our evidences that MM
serum derived EVs contain the c-src kinase and generate new c-src
positive vesicles in cultured cells suggest a potential “signaloso-
mal” function of EVs in MM. The antitumor action of chemically
modified heparins has been shown to inhibit myeloma growth
and angiogenesis via disruption of the heparanase/syndecan-1
axis (37), and our data strongly confirm the usefulness of this
therapeutic approach. The evidence that we saw on FLCs involve-
ment in EVs uptake open a new door for combined therapeutic
approaches, particularly in patients with FLCs induced kidney
failure or amyloidosis.
Multiple myeloma is one of the most frequent hematological
malignancies and combined therapeutic approaches are needed to
ameliorate the life expectancy of MM patients.
Our study shows for the first time that FLCs are involved in
EVs intracellular uptake and confirm that GAGs are also involved
in tumor derived EVs processing. The NfκB nuclear translocation
after MM EVs exposure demonstrate the transactivating role of
EVs in cancer and our discovery that anti-FLCs antibodies and
heparin are able to block this pathway open new insights in EVs
cellular biology, MM therapeutic and diagnostic approaches.
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